How to use Technologies searched

A search for a company looking for a cancer, preclinical stage, synthetic opportunity would use the selection "Biomedicine, Diagnostics" in 'Sector', 'Cancerous, neoplasmatic' in 'Disease Category', 'Drugs, Small Molecule' in 'Technology' and 'Preclinical' in 'Development Stage'.

Selection of 'Enabling Technology, Platform technology' in 'Sector' will identify all kinds of searches for technologies that can be used in more areas of life sciences than pharmaceuticals only.

Each search profile gives the name or a short description of the company behind the search, and a link allowing to contact your potential licensee.

Registered users can create non-public notifications profiles which will inform them about new Technologies Searched entries fitting their expertise as specified. In addition these profiles allow them to filter the available information more comfortably.


Lilly is looking for opportunities in oncology

Organization name

Global External Research & Development Lilly Research Laboratories Eli Lilly and Company



The vision at Lilly Research Laboratories, of which Global External R&D is a part, is a commitment to discovering, developing and acquiring innovative medicines to improve outcomes for individual patients.

With the acquisition of ImClone and the progression of their internal pipeline, one-third of their pipeline is now composed of molecules to treat cancer. They're evaluating partnership opportunities to drive the discovery and development of breakthrough medicines for cancer patients with unmet needs.

They are particularly interested in:

  • Antibody drug conjugates & small molecules based on similar concepts (guidance system-linker-payload)
  • Targeting pathways critical to cancer stem cell behavior and minimal residual disease (MRD)
  • Tumor Angiogenesis
  • Tumor metabolism and autophagy
  • Chemo / radio-resistance
  • Exploiting tumor microenvironment (hypoxia, tumor-bone interactions in MM, Prostate and BCa)
  • Emphasis on cancers with relatively strong single gene defect pathway 'addictions' that afford potential for genuine patient tailoring
  • Tumor immuno-modulatory approaches
  • Epigenetics
  • Improvements on innovative concepts (e.g. targeting bypass mechanisms for B-RAFV600E inhibition)

Currently out of scope

  • Cell cycle (next generation inhibitors of kinesins, AKs, PLKs...etc)
  • Improvements in classical cytotoxics unless much more significant than incremental chemistries and reformulations

To view the contact information, attachments and url of this profile you have to login into your account or register a new account: Login Register

Your feedback

Please click here to log in to view the complete profile.


latest entries